Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Ulcerative Colitis and Crohn's Disease), by Treatment Type (Surgery and Anti- Inflammatory Drug Administration) and Forecast 2019-2025.
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and costly disease. According to the CDC in the US, the incidence rate for Crohn's disease was 3.1 to 14.6 cases per 100,000 people per year in 2015. The incidence rate of ulcerative colitis was 2.2 to 14.3 cases per 100,000 people per year in 2015. Moreover, the prevalence of IBD in Europe is increasing, according to the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), there were 3.4 million cases of IBD in 2016. According to the WHO, the highest rates of IBD are found in, developed countries including the US and UK.
The global IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn's disease. Crohn's disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn's disease than ulcerative colitis. For Crohn's and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.
The companies which are contributing to the growth of the global IBD therapeutics market include Abbott Laboratories, AbbVie Inc., Allergan, PLC Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Research Methodology
The market study of global IBD therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.
Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
Market Segmentation:
1. Global IBD Market Research and Analysis by Disease Type
2. Global IBD Market Research and Analysis by Treatment type
The Report covers:
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and costly disease. According to the CDC in the US, the incidence rate for Crohn's disease was 3.1 to 14.6 cases per 100,000 people per year in 2015. The incidence rate of ulcerative colitis was 2.2 to 14.3 cases per 100,000 people per year in 2015. Moreover, the prevalence of IBD in Europe is increasing, according to the European Federation of Crohn's & Ulcerative Colitis Associations (EFCCA), there were 3.4 million cases of IBD in 2016. According to the WHO, the highest rates of IBD are found in, developed countries including the US and UK.
The global IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn's disease. Crohn's disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn's disease than ulcerative colitis. For Crohn's and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.
The companies which are contributing to the growth of the global IBD therapeutics market include Abbott Laboratories, AbbVie Inc., Allergan, PLC Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Research Methodology
The market study of global IBD therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.
Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
Market Segmentation:
1. Global IBD Market Research and Analysis by Disease Type
2. Global IBD Market Research and Analysis by Treatment type
The Report covers:
- Comprehensive research methodology of the global IBD therapeutics market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global IBD therapeutics market.
- Insights about market determinants which are stimulating the global IBD therapeutics market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
A selection of companies mentioned in this report includes:
- 1. Abbott Laboratories
- 2. AbbVie Inc.
- 3. Allergan, PLC
- 4. Boehringer Ingelheim International GmbH
- 5. Celgene Corp.
- 6. Daiichi Sankyo Co. Ltd.
- 7. Eli Lilly and Co.
- 8. F. Hoffmann-La Roche AG
- 9. GlaxoSmithKline PLC
- 10. Johnson & Johnson Services Inc.
- 11. Laboratory Corporation of America Holdings
- 12. Mercator Pharmaceutical Solutions
- 13. Pfizer Inc.
- 14. Pharmacosmos A/S
- 15. RPG Life Sciences Ltd.
- 16. Sanofi S.A.
- 17. Takeda pharmaceutical Co., Ltd.
- 18. UCB, Inc.
- 19. Vifor Pharma Group
